Drugs / Post-Transplant G-CSF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06412497 Background | Jun 2024 → May 2035 expected | acquired thrombocytopenia, idiopathic aplastic anemia, paroxysmal nocturnal hemoglobinuria, primary acquired red cell aplasia | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Post-Transplant G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06412497 ↗ |
| Route | Intravenous | “patients will receive G-CSF SQ or IV” NCT06412497 ↗ |
| Route | Subcutaneous | “patients will receive G-CSF SQ or IV” NCT06412497 ↗ |